Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563000, China.
Department of Pulmonary and Critical Care Medicine, The Third Affiliated Hospital of Zunyi Medical University (The First People's Hospital of Zunyi), Zunyi, Guizhou 563000, China.
Biosci Rep. 2020 Jul 31;40(7). doi: 10.1042/BSR20201710.
Numerous published studies have shown that S100A4 is frequently overexpressed in various human cancers. However, the association between S100A4 expression and prognosis or clinicopathological parameters in non-small cell lung cancer (NSCLC) remains unclear. Therefore, a meta-analysis was performed to identify the significance of S100A4 in NSCLC.
Systematic literature search was conducted using PubMed, Embase, Web of Science, the Cochrane Library, the Chinese National Knowledge Infrastructure database (CNKI), and the Wanfang database to obtain relevant articles. A combined hazard ratio (HR) and its corresponding 95% confidence interval (CI) were used to evaluate the association between S100A4 expression and prognosis in NSCLC patients. Pooled odds ratio (OR) and 95% CI were calculated to assess the association between S100A4 expression and clinicopathological features in NSCLC.
NSCLC patients with overexpression of S100A4 had a worse prognosis than patients with low expression of S100A4 (HR = 1.77, 95% CI: 1.55-2.02, P<0.001). Additionally, overexpression of S100A4 was significantly correlated to patients' age (OR = 0.67, 95% CI: 0.49-0.91, P=0.010), tumor differentiation (OR = 2.20, 95% CI: 1.69-2.85, P<0.001), lymph node metastasis (LNM) (OR = 3.70, 95% CI: 2.25-6.06, P<0.001), Tumor-Node-Metastasis (TNM) stage (OR = 3.08, 95% CI: 2.10-4.53, P<0.001), and pathological subtype (OR = 1.77, 95% CI: 1.09-2.88, P=0.020). However, there was no association between S100A4 expression and other clinicopathological features in NSCLC, including gender, tumor size, and smoking.
S100A4 overexpression was associated with tumor progression and poor prognosis in NSCLC patients. Hence, S100A4 might serve as a potential prognostic biomarker in NSCLC.
大量已发表的研究表明，S100A4 在各种人类癌症中经常过表达。然而，S100A4 表达与非小细胞肺癌（NSCLC）的预后或临床病理参数之间的关联尚不清楚。因此，进行了荟萃分析以确定 S100A4 在 NSCLC 中的意义。
使用 PubMed、Embase、Web of Science、Cochrane 图书馆、中国国家知识基础设施数据库（CNKI）和万方数据库进行系统文献检索，以获取相关文章。使用合并风险比（HR）及其相应的 95%置信区间（CI）来评估 S100A4 表达与 NSCLC 患者预后之间的关系。计算合并优势比（OR）及其 95%CI 来评估 S100A4 表达与 NSCLC 临床病理特征之间的关系。
S100A4 过表达的 NSCLC 患者的预后比 S100A4 低表达的患者差（HR=1.77，95%CI：1.55-2.02，P<0.001）。此外，S100A4 过表达与患者年龄（OR=0.67，95%CI：0.49-0.91，P=0.010）、肿瘤分化（OR=2.20，95%CI：1.69-2.85，P<0.001）、淋巴结转移（LNM）（OR=3.70，95%CI：2.25-6.06，P<0.001）、肿瘤-淋巴结-转移（TNM）分期（OR=3.08，95%CI：2.10-4.53，P<0.001）和病理亚型（OR=1.77，95%CI：1.09-2.88，P=0.020）显著相关。然而，S100A4 表达与 NSCLC 的其他临床病理特征之间没有关联，包括性别、肿瘤大小和吸烟。
S100A4 过表达与 NSCLC 患者的肿瘤进展和预后不良相关。因此，S100A4 可能成为 NSCLC 的潜在预后生物标志物。
